Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Position Boosted by Federated Hermes Inc.

Federated Hermes Inc. boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 2,132.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 525,337 shares of the company’s stock after buying an additional 501,809 shares during the quarter. Federated Hermes Inc. owned approximately 0.90% of Harmony Biosciences worth $16,968,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Harmony Biosciences by 95.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,533 shares of the company’s stock worth $50,000 after buying an additional 748 shares during the last quarter. Oakworth Capital Inc. bought a new position in Harmony Biosciences in the third quarter worth about $150,000. ELCO Management Co. LLC acquired a new position in Harmony Biosciences in the third quarter valued at approximately $210,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Harmony Biosciences during the fourth quarter valued at approximately $210,000. Finally, Raymond James & Associates bought a new position in shares of Harmony Biosciences during the third quarter valued at approximately $216,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 11,979 shares of Harmony Biosciences stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $32.00, for a total value of $383,328.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 30.80% of the company’s stock.

Analysts Set New Price Targets

HRMY has been the subject of a number of recent research reports. The Goldman Sachs Group upped their price objective on Harmony Biosciences from $25.00 to $28.00 and gave the stock a “sell” rating in a research note on Tuesday, January 9th. Mizuho cut their price objective on shares of Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $49.00 target price on shares of Harmony Biosciences in a research report on Friday, April 12th. Bank of America restated an “underperform” rating and issued a $30.00 target price on shares of Harmony Biosciences in a research report on Tuesday, January 2nd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.63.

Harmony Biosciences Stock Down 0.2 %

HRMY opened at $29.35 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.72 and a current ratio of 2.75. The company has a market capitalization of $1.67 billion, a PE ratio of 13.84, a P/E/G ratio of 0.41 and a beta of 0.73. The stock’s fifty day moving average is $31.76 and its 200-day moving average is $30.04. Harmony Biosciences Holdings, Inc. has a one year low of $18.61 and a one year high of $39.26.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.29). Harmony Biosciences had a return on equity of 27.49% and a net margin of 22.16%. The business had revenue of $168.40 million during the quarter, compared to the consensus estimate of $168.90 million. During the same quarter last year, the firm posted $1.01 earnings per share. Harmony Biosciences’s revenue was up 31.3% compared to the same quarter last year. On average, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 3 EPS for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.